Sign in to view content

Geographic Atrophy in the Canadian Treat and Extend Trial With Ranibizumab in nAMD Patients: CANTREAT Study 24-Month Results

Peter J. Kertes, MD, FRCS(C)

Video
Published 2019

Peter J. Kertes, MD, FRCS(C)

AMD Neovascular Part II Symposium

Related

Should We Ever Consider Stopping Treatment for Neovascular AMD?
Rahul N. Khurana, MD, FASRS
Updates from the Field
2020
Learnings From the Lampalizumab Chroma and Spectri Phase 3 Trials: Effect of Baseline Characteristics on Geographic Atrophy Progression
Carl D. Regillo, MD
Annual Meeting Talks
2018
Treatment of Geographic Atrophy Secondary to AMD With Pegcetacoplan: Two-Year Outcomes From the Randomized Phase 3 DERBY and OAKS Trials
Charles C Wykoff, MD, PhD, FASRS
Updates from the Field
2022

Category: AMD-Neovascular

See more